Podcast - Better Science, Better Health: Stirring the IP Pot Emil Pot was one of the founders of ActoGeniX, which was successfully acquired in 2015 by Intrexon. Emil outlines the ingredients Europe needs to build a company from scratch, and leverage home-grown Intellectual Property.
About bsbhThis author has not yet filled in any details.
So far bsbh has created 207 blog entries.
Press Room From: Morning Health Care Europe <email@example.com> Date: Fri, 5 Oct 2018 at 06:57 Subject: POLITICO Pro Morning Health Care: After Austria comes Romania — Cancer research cash To: POLITICO Europe Subscribers https://www.politico.eu/pro/politico-pro-morning-health-care-after-austria-comes-romania-cancer-research-cash-trans-fats/?utm_source=POLITICO.EU&utm_campaign=0abbd30995-EMAIL_CAMPAIGN_2018_10_04_08_23&utm_medium=email&utm_term=0_10959edeb5-0abbd30995-189777477 RESEARCH — DOES COMMISSION FUNDING MATTER? A study presented Thursday at Gastein made the argument that private funding correlates [...]
Podcast - Better Science, Better Health: VIB’s Johan Cardoen, An EU Biotech Success Story For the first podcast in our series investigating the impact and importance of IP on European biotech and innovation, we have an in-depth discussion with Johan Cardoen of VIB, Gent’s life sciences research institute in Belgium. VIB has been called by Reuters, “part [...]
Vital Transformation leads a new consortia investigating the relationship between public funding and private investment into new innovative therapies and the supporting system of IP. This project will develop original research investigating the success factors that create successful EU biotech companies and communicate the importance of IP in creating an ecosystem where investors are willing to lose everything 92% of the time, in order to fund the 8% of medical breakthroughs that succeed.
The Alliance for Regenerative Medicine (ARM) supports the efforts of the Better Science Better Health IP Consortium
ARM is the leading international advocacy organization representing the gene and cell therapy sector and consists of more than 290 members, including life sciences companies, patient advocacy groups, academic research institutions, and investors.
4 October, 7.30-8.45 CET, Bad Hofgastein
This breakfast session will offer an open debate on the role of IP in EU healthcare innovation, focused on the appropriate role and balance for both public funding and private investments, supported by new research on EU biotech success factors produced by Vital Transformation. Speakers will discuss in a pro-con format whether IP is a problem or a solution to our healthcare needs, and what role the EU will play in supporting next-generation health technologies to promote a sustainable R&D infrastructure in Europe.
EMIF: E-managing the Future of Health Data 16th-17th March 2015, Budapest Pictures An overview 16th March 2016 - Conference Dinner with keynote speech by Sarah Garner Click to view all pictures 17th March 2016 - Full Day Conference at Gerbeaud House Click to view all [...]
EMIF: E-managing the Future of Health Data 16th-17th March 2016, Budapest Speakers Richard Bergstrom, Director General, EFPIA Miklós Bacskai, Chief Strategy & Business Development Officer, Healthware Alison Bourke, Scientific Director, Real World Evidence, IMS Health Iain Buchan, Clinical Professor Public [...]
About EMIF For more information about EMIF, visit the EMIF website Thought Leader Interview: Bart Vannieuwenhuyse, Senior Director Health Information Sciences, Janssen Pharmaceutica; Coordinator EMIF Click here to read the article “When it comes to sharing health data, solving the technical solutions of data sharing is more straightforward [...]
EMIF: E-managing the Future of Health Data 16th-17th March 2015, Budapest Venues 16th March - Kempinski Hotel Corvinus Budapest Erzsébet tér 7-8, 1051 Budapest If you need a hotel room, please book via the official hotel website. http://www.kempinski.com/en/budapest/hotel-corvinus/welcome/ 17th March - Gerbeaud House 1051 Budapest [...]